(12) United States Patent (10) Patent No.: US 8,916,564 B2 Pettersson Et Al
Total Page:16
File Type:pdf, Size:1020Kb
USOO891.6564B2 (12) United States Patent (10) Patent No.: US 8,916,564 B2 Pettersson et al. (45) Date of Patent: Dec. 23, 2014 (54) SUBSTITUTED PYRIDO 1.2-APYRAZINES 7,812,040 B2 10/2010 Wager FOR THE TREATMENT OF 7,897,632 B2 3/2011 Kimura et al. 7,902,195 B2 3/2011 Hughes et al. NEURODEGENERATIVE AND 7,923.450 B2 4/2011 Baumann et al. NEUROLOGICAL DISORDERS 8,097,621 B2 1/2012 Bell et al. 8,697,673 B2 4/2014 Pettersson et al. (71) Applicant: Pfizer Inc., Groton, CT (US) 2002/0132817 A1 9/2002 Natsugari et al. 2003. O195205 A1 10, 2003 DeNinno et al. (72) Inventors: Martin Youngjin Pettersson, Littleton, 2004/0220186 Al 11/2004 Bell et al. MA (US); Douglas Scott Johnson 2006/0106035 A1 5/2006 Hendrix et al. s g s 2006/011 1372 A1 5, 2006 Hendrix et al. Concord, MA (US); Chakrapani 2007/0031416 A1 2/2007 Shoji et al. Subramanyam, South Glastonbury, CT 2007/0117798 A1 5, 2007 Kimura et al. (US); Christopher John O'Donnell, 2007/01 17839 A1 5/2007 Kimura et al. O O 2007/O155731 A1 7/2007 Butora et al. NRE's reely. 2007. O197581 A1 8, 2007 Asberometal. am Ende, Mystic, CT (US); Michael 2008, OOO9490 A1 1/2008 Williams et al. Eric Green, Boston, MA (US); Nandini 2008/0076.738 A1 3, 2008 Cai et al. Chaturbhai Patel, Waltham, MA (US); 2008. O194591 A1 8, 2008 Entwistle et al. Cory Michael Stiff, New London, CT 2008/02O7900 A1 8/2008 Kimura et al. 2008/0280948 A1 11/2008 Baumann et al. (US); Tuan Phog Tra. Ledyard, CT 2009.0062529 A1 3/2009 Kimura et al. (US); Gregory Wayne Kauffman, East 2009/0163482 A1 6/2009 McHardy et al. Greenwich, RI (US); Antonia 2009, 0215759 A1 8/2009 Baumann et al. Friederike Stepan, Providence, RI (US); 2009,0306054 A1 12/2009 Cai et al. Patrick Robert Verhoest, Newton, MA 2010, OO16373 A1 1/2010 Khilevich et al. (US) s s 2010.0041680 A1 2/2010 Rivkin 2010/0093.731 A1 4/2010 Goetschi et al. 2010, O105904 A1 4/2010 Kimura et al. (73) Assignee: Pfizer Inc., New York, NY (US) 2010, 0120874 A1 5/2010 Baumann et al. (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS EP 1145714 10, 2001 (21) Appl. No.: 14/031,163 GB 1419789 12, 1975 (22) Filed: Sep.19, 2013 (Continued) OTHER PUBLICATIONS (65) Prior Publication Data PCT Search Report and Written Opinion from International Search US 2014/0088.111A1 Mar. 27, 2014 ing Authority for PCT/IB2013/058347 dated Jan. 15, 2014. Related U.S. Application Data (Continued) (60)60) Provisionalya applicauonapplication No.No 61/703.969,909, filedIlled on Sep.Sep Primary Examiner — Douglas MWillis s (74) Attorney, Agent, or Firm — Richard V. Zanzalari (51) Int. Cl. A6 IK3I/4985 (2006.01) (57) ABSTRACT CO7D 47L/04 (2006.01) Compounds and pharmaceutically acceptable salts of the (52) U.S. Cl. compounds are disclosed, wherein the compounds have the CPC .................................... C07D 471/04 (2013.01) structure of Formula I USPC ......... 514/249; 544/349; 548/335.1; 549/429 (58) Field of Classification Search CPC .................................................. A61K 31f4985 I USPC ......... 514/249; 544/349; 548/335.1; 549/429 R7 Q R2a R2b See application file for complete search history. 24. R3 N1 N1 (56) References Cited R4b U.S. PATENT DOCUMENTS X 4 2 R 5,700,810 A 12/1997 Natsugari et al. O R5a R55 6,489,315 B1 12/2002 Natsugari et al. 7,238,721 B2 7/2007 Chen et al. 7,253,180 B2 8, 2007 Chen et al. as defined in the specification. Corresponding pharmaceuti 7,253,195 B2 8, 2007 Chen cal compositions, methods of treatment, methods of synthe 7,342,118 B2 3/2008 Brodney et al. 7,517,532 B2 4/2009 Wai et al. sis, and intermediates are also disclosed. 7,638,629 B2 12/2009 Hannam et al. 7,741,315 B2 6/2010 Vacca et al. 25 Claims, No Drawings US 8,916,564 B2 Page 2 (56) References Cited Gillman, K., et al., “Discovery and Evaluation of BMS-708 163, a Potent Selective and Orally Bioavailabley-Secretase Inhibitor'. ACS U.S. PATENT DOCUMENTS Medicinal Chemistry Letters, Mar. 22, 2010, pp. 120-124; 1(3). Goel, A., et al., “Amberlyst 15-Catalyzed Efficient synthesis of 2010/013 0495 A1 5, 2010 Forsblom et al. 5-Acetyl-4-hydroxy-coumarone and 5-Acetyl-6-hydroxy 2010.0137320 A1 6/2010 Huang et al. coumarone: Crucial Precursors for Several Naturally Occurring 2010/0204230 A1 8, 2010 Blurton et al. 2010/0222320 A1 9, 2010 Fischer et al. Furanoflavones 1’, Synlett, 2004, pp. 1990-1994, vol. 11. 2010, O247514 A1 9, 2010 Zhu et al. Grunewald, G.L., et al., “Binding Requirements of Phenolic 2010, O255.005 A1 10/2010 Zhu et al. Phenylethylamines in the BenZonorbornene skeleton at the Active 2010, O256128 A1 10/2010 Zhu et al. site of Phenylethanolamine N-Methyltransferasela,b'. Journal 2010, O297128 A1 11/2010 Huang et al. Medical Chemistry, Sep. 1986, pp. 1972-1982, 29(10). 2010/0298359 A1 11/2010 Huang et al. Haleblian, et al., “Characterization of Habits and Crystalline Modi 2010/0298372 A1 11/2010 Huang et al. fication of Solids and Their Pharmaceutical Applications”, Journal of 2010, O298381 A1 11/2010 Zhu et al. Pharmaceutical Science, Aug. 1975, pp. 1269-1288, 64(8). 2011/0009392 A1 1/2011 Zhu et al. Hashimoto, T., et al., “A Novel Gamma-secretase Modulator-Phar 2011 OOO9619 A1 1/2011 Kimura et al. macology Part”, Journal of Alzheimer's & Dementia, Jul. 2010, 2011/OO15175 A1 1/2011 Marcin et al. Supplemental, pp. S242 (PI-236), 6(4). 2011/00272.64 A1 2/2011 Huang et al. Huang, X, et al., “The Discovery of Pyridone and Pyridazone Het 2011/0053918 A1 3/2011 Zhu et al. 2011/OO70297 A1 3/2011 Cao et al. erocycles as —SecretaseModulators'. ACS Medicinal Chemistry 2011 OO82153 A1 4/2011 Aslanian et al. Letters, 2010, pp. 184-187, 1(4). 2011 0118234 A1 5, 2011 Biswas et al. Hughes, J.D., et al., “Physiochemical drug properties associated with 2011 0166132 A1 7, 2011 Hitchcock et al. in vivo toxicological outcomes. Bioorganic & Medicinal Chemistry 2011/0172427 A1 7/2011 Nakamura et al. Letters, Sep. 1, 2008, pp. 4872-4875, 18(17). 2011/02O7733 A1 8, 2011 Rivkin et al. Inamoto, K., et al., “Palladium-Catalyzed Synthesis of 2-Substituted 2011/0237580 A1 9/2011 Gijsen et al. Benzothiazoles via a C-H Functionalization/Intramolecular C–S 2011/025.1172 A1 10/2011 Rivkin et al. Bond Formation Process'. Organic Letters, 2008, pp. 5147-5150. 2011/O257156 A1 10/2011 Zhu et al. 10(22). 2011/0263.529 A1 10/2011 Xu et al. Kato, D., et al., “Microbial Deracemization of C-Substituted 2011/0275822 A1 11/2011 Minamisono et al. Carboxylic Acids: Substrate Specificity and Mechanistic Investiga 2011/028.1881 A1 11/2011 Gijsen et al. 2011/0294784 A1 12/2011 Asberomet al. tion”, Journal Organic Chemistry, Sep. 19, 2003, pp. 7234-7242, 2011/0313001 A1 12/2011 Fischer et al. 68(19). 2012/0022044 A1 1/2012 Fischer et al. Kawahara, N., et al., “A simple synthesis of dimethyl 2-pyridone-4, 2012/0022090 A1 1/2012 Gijsen et al. 5-dicarboxylate derivatives”, Journal of Heterocyclic Chemistry, 2012.0053165 A1 3/2012 Allen et al. 1989, pp. 847-852, 26(3). 2012fO252758 A1 10/2012 Pettersson et al. Kawahara, N., et al., “Synthesis and Thermal Cyclization Reactions 2014/0045790 A1 2/2014 Pettersson et al. of Methyl Isocrotonate Derivatives”. Chemical & Pharmaceutical 2014f00881.11 A1 3/2014 Pettersson et al. Bulletin, Feb. 1987, pp. 457-467, 35(2). Kouinnas, Maria Z. et al., “Modulation of Secretase Reduces FOREIGN PATENT DOCUMENTS B-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease”, Neuron, Sep. 9, 2010, pp. 769-780, 67(5). WO 994.4955 10, 1999 Lee, J.C., et al., “Facile Synthesis of Oxazoles Starting from WO 2004024.078 3, 2004 Ketones”. Synthetic Communications 2003, pp. 1611-1614, 33(9). WO 2006126081 11, 2006 Lin, Y., et al., “New Synthesis of Isoxazoles and Isothiazoles. A WO 2006126082 11, 2006 WO 2006126083 11, 2006 Convenient Synthesis of Thioenaminones from Enaminones”, Jour WO 2007063385 6, 2007 nal of Organic Chemistry, Nov. 1980, pp. 4857-4860, 45(24). WO 2007088450 8, 2007 Liu, J., et al., “Synthesis and Photophysical Properties of New Flu WO 2007088462 8, 2007 orinated Benzocxanthene Dyes as Intracellular pH Indicators'. WO 2007099423 9, 2007 Bioorganic & Medicinal Chemistry Letters, 2001, pp. 2903-2905, WO 2007138431 12/2007 11(22). WO 20081371.02 11, 2008 Liu, W., et al., “Total synthesis of Isoprekinamycin: Structural Evi WO 2009050227 4/2009 dence for Enhanced Diazonium Ion Character and Growth Inhibitory WO 2009061699 5, 2009 Activity toward Cancer Cells'. Organic Letters, 2007, pp. 2915 WO 2010.075.204 T 2010 2918, 9(15). WO 2010O98332 9, 2010 Morphy, Richard, “The Influence of Target Family and Functional WO 2010O98488 9, 2010 Activity on the Physicochemical Properties of Pre-Clinical Com WO 2010O98495 9, 2010 WO 2010O98496 9, 2010 pounds”, Journal of Medicinal Chemistry, 2006, pp. 2969-2978, WO 2011048.525 A1 4/2011 49(10). WO 2012131539 A1 10, 2012 Narender, N., et al., “Highly Efficient, Para-selective Oxychlorina WO 2013171712 A1 11 2013 tion of Aromatic Compound Using Potassium Chloride and Oxone'. Synthetic Communication 2002, pp.